Caroline Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Caroline Smith has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Cheng Zhang
University of Texas Southwestern Medical Center 1 Department of Physiology Dallas, Texas
25 shared publications - Cheryl Lewis
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
25 shared publications - Ningyan Zhang
Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, 1825 Pressler Street, Houston, TX 77030, USA
25 shared publications - Ryan Huang
Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas
25 shared publications - Samuel John
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas
25 shared publications - Xiaoye Liu
Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA
25 shared publications
Latest Publications
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (118) , eadt7832
Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer
The mechanisms underlying tumor cell–myeloid cell interactions in the tumor microenvironment (TME) remain unclear, and predictive biomarkers for patient response to myeloid checkpoint blockade are lacking. This study identified specific binding between tight junction claudins (CLDNs) and leukocyte immunoglobulin-like receptor subfamily B2 (LILRB2) and LILRB5. In multiple human cancer cohorts, the spatial proximity of LILRB2-positive macrophages to CLDN-expressing cancer cells correlated with clinical outcomes, highlighting this spatial relationship as a potential biomarker. In syngeneic LILRB2-transgenic and humanized mouse models, CLDN18.2-LILRB2 interactions triggered bidirectional signaling, enhanced the immunosuppressive activity of myeloid cells, and accelerated tumor progression. These effects were reversed by LILRB2 blockade. The CLDN-LILRB2 axis sustained immunosuppression by regulating NF-κB and STAT signaling pathways. Our findings reveal a mechanism of myeloid cell regulation by tight junction proteins in the TME, offering a rationale for targeting this pathway in cancer therapy.
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (118) , eadt7832
Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer
The mechanisms underlying tumor cell–myeloid cell interactions in the tumor microenvironment (TME) remain unclear, and predictive biomarkers for patient response to myeloid checkpoint blockade are lacking. This study identified specific binding between tight junction claudins (CLDNs) and leukocyte immunoglobulin-like receptor subfamily B2 (LILRB2) and LILRB5. In multiple human cancer cohorts, the spatial proximity of LILRB2-positive macrophages to CLDN-expressing cancer cells correlated with clinical outcomes, highlighting this spatial relationship as a potential biomarker. In syngeneic LILRB2-transgenic and humanized mouse models, CLDN18.2-LILRB2 interactions triggered bidirectional signaling, enhanced the immunosuppressive activity of myeloid cells, and accelerated tumor progression. These effects were reversed by LILRB2 blockade. The CLDN-LILRB2 axis sustained immunosuppression by regulating NF-κB and STAT signaling pathways. Our findings reveal a mechanism of myeloid cell regulation by tight junction proteins in the TME, offering a rationale for targeting this pathway in cancer therapy.
- 20 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 746-750
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort
Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children’s Oncology Group (COG) Phase III trial AAML1831 based on previous trials. It remains unknown whether the cytomolecular risk profiles are generalizable to the real-world. We addressed this knowledge gap using a nationally representative real-world cohort of 913 pediatric AML patients. Distributions of cytomolecular risk profiles and individual markers were comparable for trial-enrolled and non-enrolled patients, as well as across social drivers of trial enrollment (race/ethnicity, language, insurance, acuity). Compared to patients with only favorable cytomolecular markers (4-year overall survival [OS] = 89.48%; 95% CI = 84.46% to 92.95%), patients with both favorable and unfavorable (hazards ratio [HR] = 2.49, 95% CI = 1.18 to 5.23), neutral (HR = 4.33, 95% CI = 2.75 to 6.82), and only unfavorable (HR = 5.80, 95% CI = 3.70 to 9.11) markers all had increased hazards of death. Cytomolecular risk informed by trial data appears to be generalizable to the real-world setting in pediatric AML.
- 20 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 746-750
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort
Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children’s Oncology Group (COG) Phase III trial AAML1831 based on previous trials. It remains unknown whether the cytomolecular risk profiles are generalizable to the real-world. We addressed this knowledge gap using a nationally representative real-world cohort of 913 pediatric AML patients. Distributions of cytomolecular risk profiles and individual markers were comparable for trial-enrolled and non-enrolled patients, as well as across social drivers of trial enrollment (race/ethnicity, language, insurance, acuity). Compared to patients with only favorable cytomolecular markers (4-year overall survival [OS] = 89.48%; 95% CI = 84.46% to 92.95%), patients with both favorable and unfavorable (hazards ratio [HR] = 2.49, 95% CI = 1.18 to 5.23), neutral (HR = 4.33, 95% CI = 2.75 to 6.82), and only unfavorable (HR = 5.80, 95% CI = 3.70 to 9.11) markers all had increased hazards of death. Cytomolecular risk informed by trial data appears to be generalizable to the real-world setting in pediatric AML.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S1. Eph receptors do not bind to LILRB1, LILRB3, LILRB4 and LAIR1.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S1. Eph receptors do not bind to LILRB1, LILRB3, LILRB4 and LAIR1.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Immunosuppressive myeloid cells are critical obstacles to T cell–centered immune checkpoint blockade therapies, which have been successful in treating a fraction of patients with cancer. How tumor cells interact with myeloid cells to regulate immune responses and tumor development is unclear. In this study, we report that certain membrane tyrosine kinase Eph receptors, including EphA7 and EphB1, specifically bind the immune inhibitory receptors leukocyte Ig-like receptor family B 5 (LILRB5) and LILRB2. These Eph receptors induce LILRB5-mediated signaling activation, and LILRB5 also activates Eph receptor signaling. Activation of LILRB5 promoted immunosuppressive marker expression and inhibited activating marker expression on myeloid cells from patients with cancer in vitro. Upon myeloid cell–specific expression of LILRB5 in transgenic mice, the interaction between the Eph receptor on tumor cells and LILRB5 on myeloid cells led to increased tumor growth, increased immunosuppressive myeloid cells, and decreased frequencies of functional T cells compared with control mice. Eph-induced LILRB5 signaling and functions were reversed by LILRB5 blockade. In sum, certain Eph receptors functionally interact with the myeloid checkpoint receptor LILRB5 resulting in bidirectional signaling, and LILRB5 plays an important role in supporting immunosuppressive myeloid cells and sustaining tumor development.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Immunosuppressive myeloid cells are critical obstacles to T cell–centered immune checkpoint blockade therapies, which have been successful in treating a fraction of patients with cancer. How tumor cells interact with myeloid cells to regulate immune responses and tumor development is unclear. In this study, we report that certain membrane tyrosine kinase Eph receptors, including EphA7 and EphB1, specifically bind the immune inhibitory receptors leukocyte Ig-like receptor family B 5 (LILRB5) and LILRB2. These Eph receptors induce LILRB5-mediated signaling activation, and LILRB5 also activates Eph receptor signaling. Activation of LILRB5 promoted immunosuppressive marker expression and inhibited activating marker expression on myeloid cells from patients with cancer in vitro. Upon myeloid cell–specific expression of LILRB5 in transgenic mice, the interaction between the Eph receptor on tumor cells and LILRB5 on myeloid cells led to increased tumor growth, increased immunosuppressive myeloid cells, and decreased frequencies of functional T cells compared with control mice. Eph-induced LILRB5 signaling and functions were reversed by LILRB5 blockade. In sum, certain Eph receptors functionally interact with the myeloid checkpoint receptor LILRB5 resulting in bidirectional signaling, and LILRB5 plays an important role in supporting immunosuppressive myeloid cells and sustaining tumor development.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S6. EphB1 expression on tumor cells promotes T cell exhaustion in LILRB5 transgenic mice.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S6. EphB1 expression on tumor cells promotes T cell exhaustion in LILRB5 transgenic mice.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S2. LILRB5-ECD induces EphB1 phosphorylation.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S2. LILRB5-ECD induces EphB1 phosphorylation.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S3. EphB1 activates LILRB5 in vitro and promote immune suppressive functions.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S3. EphB1 activates LILRB5 in vitro and promote immune suppressive functions.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S4. Myeloid specific transgenic mice of LILRB5.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S4. Myeloid specific transgenic mice of LILRB5.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S5. EphA7 overexpression on LLC cells supports tumor growth in myeloid-specific LILRB5 transgenic mice.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S5. EphA7 overexpression on LLC cells supports tumor growth in myeloid-specific LILRB5 transgenic mice.